Christopher Benecchi - 13 Feb 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Business Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
Issuer symbol
SAGE
Transactions as of
13 Feb 2024
Transactions value $
$0
Form type
4
Filing time
15 Feb 2024, 17:02:15 UTC
Previous filing
15 Feb 2023
Next filing
07 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +13,500 +2.28% $0 19,430 13 Feb 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +27,000 $0 27,000 13 Feb 2024 Common Stock 27,000 $23.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of common stock issuable under 13,500 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on February 13, 2025.
F2 Reflects beneficial ownership balance which includes 670 shares purchased on June 30, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.
F3 The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 6,750 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 20,250 shares vesting in 36 equal monthly installments thereafter.